Abstract
Lung Cancer Screening (LCS) via Low Dose Computed Tomography (LDCT) reduces lung cancer mortality, yet utilization has remained low even before the onset of the COVID-19 pandemic and the resulting disruption to screening (Aberle et al., 2011; de Koning et al., 2020; Jemal, 2017). The impact of COVID-19 on specific LCS program components and how this has led to differences in LCS uptake is unknown. Understanding program-level barriers experienced in the context of COVID-19 will help guide resource allocation and inform optimization of LCS in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
